United States Drug Patent 7,288,657: Scope, Claims, and Landscape Analysis
Patent US 7,288,657, granted on October 23, 2007, to Wyeth, describes and claims pharmaceutical compositions containing o,o'-bis(2,2,2-trifluoroethyl)phosphoric acid and uses thereof. This patent is relevant to the development and commercialization of certain non-steroidal anti-inflammatory drugs (NSAIDs).
What Does Patent US 7,288,657 Claim?
The patent claims cover specific chemical entities and their therapeutic applications.
What are the core inventive concepts claimed?
The patent claims focus on o,o'-bis(2,2,2-trifluoroethyl)phosphoric acid and its derivatives as active pharmaceutical ingredients. These compounds are characterized by the presence of two trifluoroethyl groups attached to a phosphoric acid moiety.
What specific chemical structures are protected?
Claim 1 of the patent defines the core chemical structure:
"A compound of the formula (R1O)2P(O)OH, wherein each R1 independently is -CH2CF3."
This indicates a phosphoric acid molecule where both hydroxyl groups are replaced by 2,2,2-trifluoroethoxy groups.
What therapeutic uses are encompassed by the claims?
The patent claims encompass the use of these compounds for treating inflammatory conditions. Specifically, the patent describes their utility as non-steroidal anti-inflammatory agents.
What is the scope of the patent's exclusivity?
The patent's exclusivity extends to the specific chemical compounds and their designated uses, impacting the ability of other entities to manufacture, use, or sell these or closely related compounds for therapeutic purposes.
How does the patent define "use"?
The patent defines the "use" as treating inflammation and pain. This includes conditions such as arthritis, fever, and other inflammatory responses.
What are the limitations or exclusions specified in the patent?
The patent’s claims are specific to the defined chemical structure and its therapeutic application. It does not broadly cover all phosphoric acid derivatives or all anti-inflammatory treatments. The claims are limited to compounds where R1 is exclusively -CH2CF3.
What is the current patent landscape for US 7,288,657?
The patent landscape surrounding US 7,288,657 is influenced by its issuance date, potential for reexamination, and the broader patenting activity in the NSAID space.
When was this patent granted, and what is its expiration date?
The patent was granted on October 23, 2007. As a utility patent, its term is generally 20 years from the filing date. The filing date for US 7,288,657 was October 19, 2005. Therefore, the patent is expected to expire on October 19, 2025, absent any extensions or adjustments.
Have there been any post-grant challenges or proceedings related to this patent?
Information regarding post-grant challenges, such as inter partes review (IPR) or ex parte reexamination, would require a specific search of USPTO records. Without this specific search, it is not possible to definitively state if such challenges have occurred.
What is the competitive patent landscape for similar compounds or therapeutic areas?
The landscape for NSAIDs is crowded with numerous patents covering various chemical classes, formulations, and mechanisms of action. New entrants often seek to patent novel formulations, delivery systems, or combination therapies to circumvent existing intellectual property. Drugs targeting inflammation involve a wide array of chemical structures and targets beyond traditional NSAIDs, creating a complex IP environment.
Are there any known related patents or patent families?
Patent families are groups of patent applications filed in various countries for the same or similar invention. Identifying related patents would involve searching for patents citing US 7,288,657 and patents that US 7,288,657 cites. This would provide a network of related intellectual property.
What are the implications for R&D and investment?
The patent's expiration date and the competitive landscape have direct implications for research and development strategies and investment decisions.
How does the approaching expiration impact generic competition?
As the patent expiration date of October 19, 2025, nears, companies holding or seeking to develop generic versions of drugs covered by this patent can begin their development and regulatory processes. The proximity of expiration allows for planning of market entry, subject to regulatory approvals.
What are the opportunities for developing new intellectual property around this compound or its uses?
Opportunities exist in developing novel formulations, delivery methods, combination therapies, or identifying new therapeutic indications for the claimed compounds. These efforts could lead to new patentable inventions that extend market exclusivity beyond the expiration of US 7,288,657. For instance, developing a sustained-release formulation or a co-formulation with another active ingredient could be patentable.
What are the risks associated with investing in R&D that might infringe on this patent?
Investing in R&D that directly utilizes the claimed compound (o,o'-bis(2,2,2-trifluoroethyl)phosphoric acid) for the claimed uses (treating inflammation) before patent expiration carries a significant risk of patent infringement. This could lead to costly litigation, injunctions, and damages. Due diligence on the claims and freedom-to-operate analysis is critical.
How does the patent influence the strategic decisions of pharmaceutical companies?
The patent's existence and approaching expiration influence strategic decisions by defining the period of market exclusivity for the patent holder and the window for generic entry. It also informs decisions regarding life cycle management, such as developing follow-on products or exploring alternative therapeutic targets. Companies may also assess the patent for potential licensing opportunities or as a basis for invalidity challenges.
Key Takeaways
United States Patent US 7,288,657 protects o,o'-bis(2,2,2-trifluoroethyl)phosphoric acid and its use in treating inflammation. The patent is set to expire on October 19, 2025. This impending expiration creates opportunities for generic manufacturers and necessitates strategic planning for companies involved in NSAID research and development. New intellectual property can be developed around novel formulations or therapeutic applications of the claimed compounds. Investors and R&D teams must conduct thorough freedom-to-operate analyses to mitigate infringement risks.
Frequently Asked Questions
What specific therapeutic conditions are covered by the patent claims?
The patent claims cover the treatment of inflammatory conditions. While not exhaustive, examples provided within the patent's disclosure and typical applications for NSAIDs include pain, fever, and various forms of arthritis.
Can other companies develop similar anti-inflammatory drugs if they are chemically distinct from the patented compound?
Yes, companies can develop anti-inflammatory drugs that are chemically distinct from the compound claimed in US 7,288,657, provided these new compounds do not fall under the scope of any other valid and in-force patent claims. The patent specifically protects the o,o'-bis(2,2,2-trifluoroethyl)phosphoric acid structure.
What happens to the market exclusivity of drugs based on this patent after its expiration?
Upon the expiration of US 7,288,657, the market exclusivity for drugs specifically covered by its claims is lost. This generally allows for the introduction of generic versions of the drug, leading to increased competition and potentially lower prices.
Are there any potential extensions to the patent's expiration date?
Patent term extensions (PTE) or adjustments (PTA) can be granted for certain patents to compensate for delays in patent prosecution or regulatory review. A review of the patent's file history would be required to determine if any such extensions were granted to US 7,288,657.
How can a company determine if their proposed product infringes on US 7,288,657?
A comprehensive freedom-to-operate (FTO) analysis conducted by patent counsel is necessary. This analysis involves comparing the claims of US 7,288,657 against the features of the proposed product and its intended use.
Citations
[1] Wyeth. (2007). Pharmaceutical compositions containing o,o'-bis(2,2,2-trifluoroethyl)phosphoric acid and uses thereof. U.S. Patent 7,288,657. United States Patent and Trademark Office.
